Search - tctmd.com

Displaying 1 - 15 of 15

Sort: Relevancy | Date

News Conference News TCT 2018

RADIOSOUND-HTN Suggests Ultrasound May Be Best for Renal Denervation

Todd Neale

September 26, 2018

Even With PSP, Bioresorbable Scaffold Falls Short in ABSORB-COMPARE and ABSORB IV Trials

News Conference News TCT 2018

Even With PSP, Bioresorbable Scaffold Falls Short in COMPARE-ABSORB and ABSORB IV Trials

Michael O'Riordan

September 25, 2018

News Opinion Editor's Corner TCT 2018

TCT 2018, Day Four: Bioresorbable Scaffolds, Renal Denervation, Head-to-Head TAVR, INOCA, and . . . That’s a Wrap!

Shelley Wood

September 25, 2018

News Conference News TCT 2018

Prematurely Halted Pilot Study Snaps Recent Winning Streak for Renal Denervation

Todd Neale

September 25, 2018

Presentation TCT 2018

Flash Debate #1: Based on What We Dont Know - Culprit Lesion Only PCI With a Conservative Approach Is the Preferred Strategy!

Presenter: Anthony H. Gershlick, Pieter C. Smits, Deepak L. Bhatt

September 24, 2018

News Conference News TCT 2018

OAC-ALONE: No Clear Answer for Best Therapy Beyond 1 Year After PCI in A-fib Patients

Todd Neale

September 24, 2018

Presentation TCT 2018

ESC 2018 Late Breaking Trial #2 - MitraFR: What I Liked and What I Question

Presenter: Deepak L. Bhatt, Gregg W. Stone, Stephan Windecker

September 23, 2018

Presentation TCT 2018

ESC 2018 Late Breaking Trial #1 Global Leaders: What I Liked and What I Question

Presenter: Deepak L. Bhatt, Gregg W. Stone, Giuseppe Biondi-Zoccai

September 23, 2018

Presentation TCT 2018

ACC 2018 Late Breaking Trial #2- COMPASS : What I Liked and What I Question

Presenter: Deepak L. Bhatt, Gregg W. Stone, Kurt Huber

September 23, 2018

Presentation TCT 2018

ACC 2018 Late Breaking Trial #1 - ODYSSEY Outcomes: What I Liked and What I Question

Presenter: Deepak L. Bhatt, Gregg W. Stone, Otavio Berwanger, Peter Juni, Sanjay Kaul, Roxana Mehran, E. Magnus Ohman, Stuart J. Pocock, Giulio Stefanini

September 23, 2018

Presentation TCT 2018

COMPASS Trial Revisited: Weighing Rivaroxaban Secondary Prevention vs DAPT After PCI

Presenter: Deepak L. Bhatt, Tullio Palmerini, Michael Maeng

September 23, 2018

Presentation TCT 2018

Ultra-Short DAPT (1 3 Months): For Which Patients and Stents Do We Have Evidence?

Presenter: Deepak L. Bhatt, Tullio Palmerini, Philip M. Urban

September 23, 2018

Presentation TCT 2018

Patient Selection for Prolonged DAPT: Risk Scores or Wise Clinical Judgement?

Presenter: Deepak L. Bhatt, Tullio Palmerini, Usman Baber

September 23, 2018

Presentation TCT 2018

Who Is the High Bleeding Risk Patient, and How Should DAPT Duration Be Weighed Against Ischemic Risk?

Presenter: Deepak L. Bhatt, Tullio Palmerini, Roxana Mehran

September 23, 2018

Presentation TCT 2018

Utility of Cangrelor During PCI and Bridging Who Benefits Most?

Presenter: John A. Bittl, C. Michael Gibson, Deepak L. Bhatt

September 23, 2018

Advertisement

RADIOSOUND-HTN Suggests Ultrasound May Be Best for Renal Denervation

Even With PSP, Bioresorbable Scaffold Falls Short in COMPARE-ABSORB and ABSORB IV Trials

TCT 2018, Day Four: Bioresorbable Scaffolds, Renal Denervation, Head-to-Head TAVR, INOCA, and . . . That’s a Wrap!

Prematurely Halted Pilot Study Snaps Recent Winning Streak for Renal Denervation

Flash Debate #1: Based on What We Dont Know - Culprit Lesion Only PCI With a Conservative Approach Is the Preferred Strategy!

OAC-ALONE: No Clear Answer for Best Therapy Beyond 1 Year After PCI in A-fib Patients

ESC 2018 Late Breaking Trial #2 - MitraFR: What I Liked and What I Question

ESC 2018 Late Breaking Trial #1 Global Leaders: What I Liked and What I Question

ACC 2018 Late Breaking Trial #2- COMPASS : What I Liked and What I Question

ACC 2018 Late Breaking Trial #1 - ODYSSEY Outcomes: What I Liked and What I Question

COMPASS Trial Revisited: Weighing Rivaroxaban Secondary Prevention vs DAPT After PCI

Ultra-Short DAPT (1 3 Months): For Which Patients and Stents Do We Have Evidence?

Patient Selection for Prolonged DAPT: Risk Scores or Wise Clinical Judgement?

Who Is the High Bleeding Risk Patient, and How Should DAPT Duration Be Weighed Against Ischemic Risk?

Utility of Cangrelor During PCI and Bridging Who Benefits Most?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content